

COVID-19 Vaccine Comparison

Company	Platform	Doses	Non-clinical results	Number of people who got vaccine	Protection from hospitalization/death due to COVID-19	Protection from severe disease from COVID-19 (may not be hospital)	Efficacy against milder disease from COVID-19	EUA
	mRNA-1273 mRNA in lipid nanoparticle	2	Neutralizing Abs; Strong Th1 and Th2 response; protection from challenge	~15,000	100%	100% (30 cases in placebo arm; 0 in vaccine)	94.1%	Y
	BNT162b2 mRNA in lipid nanoparticle	2	Neutralizing Abs; Strong Th1 and Th2 response; protection from challenge	~18,600	100%	100% (9 cases in placebo arm; 0 in vaccine)	95%	Y
	AZD 1222 Non-replicating Chimp Adenovirus/ DNA	2	Neutralizing Abs; Strong Th1 and Th2 response; protection from challenge	~5,800	100%	100% (10 cases in placebo arm; 0 in vaccine)	90% half-full dose; 70% overall	N
	JNJ-78436725 Non-replicating human adenovirus/ DNA	1	Neutralizing Abs; Strong Th1 and Th2 response; protection from challenge	~22,000	100%	85% (across South Africa, U.S., Latin America)	72% U.S.; 66% Latin America; 57% S. Africa	Y
	NCX-CoV2373 Spike protein/RBD + Matrix M adjuvant	2	Neutralizing Abs; protection from challenge	~9,700	100%		89.3% UK; 60% S. Africa	N
	Ad26 and Ad5 adenovirus/DNA	2	Neutralizing Abs; Strong Th1 and Th2	~11,360	100%	100% (20 in placebo; 0 vaccine)	91.4%	N

SOURCE: Monica Gandhi, MD, MPH, 2021, DocWire News®

<https://www.docwirenews.com/docwire-pick/infectious-disease-specialist-says-vaccinated-people-may-not-need-to-mask-distance-around-others-who-are-vaccinated/>